Test of Excessive Anesthetic Fresh Gas Flow Alerting in the Electronic Medical Record to Reduce Excessive Fresh Gas Flow
Sponsor
Stanford University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06138626
Collaborator
(none)
300
1
2
12
24.9
Study Details
Study Description
Brief Summary
The primary objective of this quality improvement intervention is to test the efficacy of excessive fresh gas flow alerting in the electronic medical record for anesthesia providers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
300 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Anesthetic Fresh Gas Flow Alert Test
Actual Study Start Date
:
Nov 15, 2023
Anticipated Primary Completion Date
:
Nov 15, 2024
Anticipated Study Completion Date
:
Nov 15, 2024
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Alert active Anesthesia provider will see alert when fresh gas flow is excessive |
Behavioral: Alert
An alert that appears when anesthetic fresh gas flow is excessive
|
| No Intervention: Alert inactive Anesthesia provider will not see alert when fresh gas flow is excessive |
Outcome Measures
Primary Outcome Measures
- Mean change in average fresh gas flow from baseline at 90 days [Baseline, day 90]
Mean change in average total fresh gas flow, in liters per minute as recorded in the electronic medical record, when administering sevoflurane, averaged over 1 week at baseline and over 1 week at 90 days
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Anesthesia provider using electronic medical record at study site
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Stanford University | Palo Alto | California | United States | 94305 |
Sponsors and Collaborators
- Stanford University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Daniel Gessner,
Clinical Assistant Professor,
Stanford University
ClinicalTrials.gov Identifier:
NCT06138626
Other Study ID Numbers:
- 63548
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No